Difference between revisions of "Thyroid cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 33: Line 33:
 
|-
 
|-
 
|}
 
|}
 +
====Chemotherapy====
 
*[[Lenvatinib (Lenvima)]] 24 mg PO once per day on days 1 to 28
 
*[[Lenvatinib (Lenvima)]] 24 mg PO once per day on days 1 to 28
 
**Per the package insert, patients with creatinine clearance of <30 mL/min by Cockroft-Gault or Child-Pugh C severe hepatic impairment should receive [[Lenvatinib (Lenvima)]] 14 mg PO once per day
 
**Per the package insert, patients with creatinine clearance of <30 mL/min by Cockroft-Gault or Child-Pugh C severe hepatic impairment should receive [[Lenvatinib (Lenvima)]] 14 mg PO once per day
Line 79: Line 80:
 
|}
 
|}
 
===Regimen {{#subobject:d4c2dd|Variant=1}}===
 
===Regimen {{#subobject:d4c2dd|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|'''Comparator'''
 +
|-
 +
|[http://jco.ascopubs.org/content/29/19/2660.long Kurzrock et al. 2011]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 86: Line 92:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Non-randomized</span>
 
border-style:solid;">Non-randomized</span>
−
 
+
|
 +
|-
 +
|[http://jco.ascopubs.org/content/31/29/3639.long Elisei et al. 2013]
 +
|<span
 +
style="background:#00cd00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase III</span>
 +
|[[#Placebo_2|Placebo]]
 +
|-
 +
|}
 +
====Chemotherapy====
 
*[[Cabozantinib (Cometriq)]] 140 mg PO once per day, at least 2 hours before or 1 hour after meals  
 
*[[Cabozantinib (Cometriq)]] 140 mg PO once per day, at least 2 hours before or 1 hour after meals  
  
 
===References===
 
===References===
−
# Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23. [http://jco.ascopubs.org/content/29/19/2660.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21606412 PubMed]
+
# Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. Epub 2011 May 23. [http://jco.ascopubs.org/content/29/19/2660.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21606412 PubMed]
−
*[http://cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf Cabozantinib (Cometriq) package insert]
+
# Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. [http://jco.ascopubs.org/content/31/29/3639.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24002501 PubMed]
  
 
==Placebo {{#subobject:c1dced|Regimen=1}}==
 
==Placebo {{#subobject:c1dced|Regimen=1}}==
Line 113: Line 131:
 
border-style:solid;">Phase III</span>
 
border-style:solid;">Phase III</span>
 
|[[Thyroid_cancer#Vandetanib_.28Caprelsa.29|Vandetanib]]
 
|[[Thyroid_cancer#Vandetanib_.28Caprelsa.29|Vandetanib]]
 +
|-
 +
|[http://jco.ascopubs.org/content/31/29/3639.long Elisei et al. 2013]
 +
|<span
 +
style="background:#00cd00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase III</span>
 +
|[[#Cabozantinib_.28Cometriq.29|Cabozantinib]]
 
|-
 
|-
 
|}
 
|}
Line 120: Line 147:
 
===References===
 
===References===
 
# Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. [http://jco.ascopubs.org/content/30/2/134.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22025146 PubMed]
 
# Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. [http://jco.ascopubs.org/content/30/2/134.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22025146 PubMed]
 +
# Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. [http://jco.ascopubs.org/content/31/29/3639.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24002501 PubMed]
  
 
==Sorafenib (Nexavar) {{#subobject:7e7480|Regimen=1}}==
 
==Sorafenib (Nexavar) {{#subobject:7e7480|Regimen=1}}==
Line 127: Line 155:
 
|}
 
|}
 
===Regimen {{#subobject:1e2f21|Variant=1}}===
 
===Regimen {{#subobject:1e2f21|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://jco.ascopubs.org/content/28/14/2323.long Lam et al. 2010]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 134: Line 166:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
−
 
+
|-
 +
|}
 +
====Chemotherapy====
 
*[[Sorafenib (Nexavar)]] 400 mg PO BID
 
*[[Sorafenib (Nexavar)]] 400 mg PO BID
  
Line 146: Line 180:
 
|}
 
|}
 
===Regimen {{#subobject:7e9b73|Variant=1}}===
 
===Regimen {{#subobject:7e9b73|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://clincancerres.aacrjournals.org/content/16/21/5260.long Carr et al. 2010]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 153: Line 191:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
−
 
+
|-
 +
|}
 +
====Chemotherapy====
 
*[[Sunitinib (Sutent)]] 37.5 mg PO once per day
 
*[[Sunitinib (Sutent)]] 37.5 mg PO once per day
  
Line 178: Line 218:
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
 
|
 
|
−
|-
 
−
!colspan="4" align="center"|
 
 
|-
 
|-
 
|[http://jco.ascopubs.org/content/30/2/134.long Wells et al. 2011]
 
|[http://jco.ascopubs.org/content/30/2/134.long Wells et al. 2011]
Line 191: Line 229:
 
|-
 
|-
 
|}
 
|}
−
 
+
====Chemotherapy====
 
*[[Vandetanib (Caprelsa)]] 300 mg PO once per day
 
*[[Vandetanib (Caprelsa)]] 300 mg PO once per day
  
Line 210: Line 248:
 
|-
 
|-
 
|}
 
|}
−
 
+
====Chemotherapy====
 
*[[Vandetanib (Caprelsa)]] 100 mg PO once per day
 
*[[Vandetanib (Caprelsa)]] 100 mg PO once per day
  
Line 229: Line 267:
 
|}
 
|}
 
===Regimen {{#subobject:aff447|Variant=1}}===
 
===Regimen {{#subobject:aff447|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://jco.ascopubs.org/content/26/29/4708.long Cohen et al. 2008]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 236: Line 278:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
−
 
+
|-
 +
|[http://onlinelibrary.wiley.com/doi/10.1002/cncr.28766/full Locati et al. 2014]
 +
|<span
 +
style="background:#EEEE00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase II</span>
 +
|-
 +
|}
 +
====Chemotherapy====
 
*[[Axitinib (Inlyta)]] 5 mg PO BID
 
*[[Axitinib (Inlyta)]] 5 mg PO BID
  
 
===References===
 
===References===
 
# Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. [http://jco.ascopubs.org/content/26/29/4708.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18541897 PubMed]
 
# Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. [http://jco.ascopubs.org/content/26/29/4708.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18541897 PubMed]
 +
## '''Update:''' Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. Epub 2014 Oct 15. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236619/ link to PMC article] [http://www.ncbi.nlm.nih.gov/pubmed/25315258 PubMed]
 +
# Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 Sep 1;120(17):2694-703. Epub 2014 May 20. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.28766/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24844950 PubMed]
  
 
==Sorafenib (Nexavar) {{#subobject:31cae2|Regimen=1}}==
 
==Sorafenib (Nexavar) {{#subobject:31cae2|Regimen=1}}==
Line 248: Line 302:
 
|}
 
|}
 
===Regimen {{#subobject:e09f77|Variant=1}}===
 
===Regimen {{#subobject:e09f77|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://jco.ascopubs.org/content/26/29/4714.long Gupta-Abramson et al. 2008]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 255: Line 313:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
−
 
+
|-
 +
|}
 +
====Chemotherapy====
 
*[[Sorafenib (Nexavar)]] 400 mg PO BID
 
*[[Sorafenib (Nexavar)]] 400 mg PO BID
  
Line 267: Line 327:
 
|}
 
|}
 
===Regimen {{#subobject:d1cea4|Variant=1}}===
 
===Regimen {{#subobject:d1cea4|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://clincancerres.aacrjournals.org/content/16/21/5260.long Carr et al. 2010]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 274: Line 338:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
−
 
+
|-
 +
|}
 +
====Chemotherapy====
 
*[[Sunitinib (Sutent)]] 37.5 mg PO once per day
 
*[[Sunitinib (Sutent)]] 37.5 mg PO once per day
  
 
===References===
 
===References===
 
# Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. [http://clincancerres.aacrjournals.org/content/16/21/5260.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20847059 PubMed]
 
# Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. [http://clincancerres.aacrjournals.org/content/16/21/5260.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20847059 PubMed]
 +
 +
[[Category:Chemotherapy regimens]]
 +
[[Category:Solid oncology regimens]]

Revision as of 02:41, 14 August 2016

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

3 regimens on this page
3 variants on this page


Differentiated thyroid cancer

Lenvatinib (Lenvima)

back to top

Regimen

Study Evidence Comparator
Schlumberger et al. 2015 (SELECT) Phase III Placebo

Chemotherapy

  • Lenvatinib (Lenvima) 24 mg PO once per day on days 1 to 28
    • Per the package insert, patients with creatinine clearance of <30 mL/min by Cockroft-Gault or Child-Pugh C severe hepatic impairment should receive Lenvatinib (Lenvima) 14 mg PO once per day

28-day cycles, given until progression of disease, or unacceptable toxicity

References

  1. Lenvatinib (Lenvima) package insert
  2. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30. link to original article PubMed

Placebo

back to top

Regimen

Study Evidence Comparator
Schlumberger et al. 2015 (SELECT) Phase III Lenvatinib

No active antineoplastic treatment.

References

  1. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30. link to original article PubMed

Medullary thyroid cancer

Cabozantinib (Cometriq)

back to top

Regimen

Study Evidence Comparator
Kurzrock et al. 2011 Non-randomized
Elisei et al. 2013 Phase III Placebo

Chemotherapy

References

  1. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. Epub 2011 May 23. link to original article contains verified protocol PubMed
  2. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. link to original article contains verified protocol PubMed

Placebo

back to top

Regimen

Study Evidence Comparator
Wells et al. 2011 Phase III Vandetanib
Elisei et al. 2013 Phase III Cabozantinib

No antineoplastic treatment. Included for reference purposes only.

References

  1. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. link to original article contains verified protocol PubMed
  2. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864. link to original article contains verified protocol PubMed

Sorafenib (Nexavar)

back to top

Regimen

Study Evidence
Lam et al. 2010 Phase II

Chemotherapy

References

  1. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010 May 10;28(14):2323-30. Epub 2010 Apr 5. link to original article contains verified protocol PubMed

Sunitinib (Sutent)

back to top

Regimen

Study Evidence
Carr et al. 2010 Phase II

Chemotherapy

References

  1. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. link to original article contains verified protocol PubMed

Vandetanib (Caprelsa)

back to top

Regimen #1

Study Evidence Comparator
Wells et al. 2010 Phase II
Wells et al. 2011 Phase III Placebo

Chemotherapy

Continued until progression or intolerance

Regimen #2

Study Evidence
Robinson et al. 2010 Phase II, <20 patients

Chemotherapy

Continued until progression or intolerance

At progression, eligible patients could increase the dose to 300 mg PO once per day; see paper for details.

References

  1. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010 Feb 10;28(5):767-72. Epub 2010 Jan 11. link to original article contains verified protocol PubMed
  2. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. Epub 2010 Apr 6. link to original article contains verified protocol PubMed content property of HemOnc.org
  3. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. link to original article contains verified protocol PubMed

Various histologies

Axitinib (Inlyta)

back to top

Regimen

Study Evidence
Cohen et al. 2008 Phase II
Locati et al. 2014 Phase II

Chemotherapy

References

  1. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. link to original article contains verified protocol PubMed
    1. Update: Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. Epub 2014 Oct 15. link to PMC article PubMed
  2. Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 Sep 1;120(17):2694-703. Epub 2014 May 20. link to original article contains verified protocol PubMed

Sorafenib (Nexavar)

back to top

Regimen

Study Evidence
Gupta-Abramson et al. 2008 Phase II

Chemotherapy

References

  1. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. Epub 2008 Jun 9. link to original article contains verified protocol PubMed

Sunitinib (Sutent)

back to top

Regimen

Study Evidence
Carr et al. 2010 Phase II

Chemotherapy

References

  1. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Thyroid_cancer&oldid=11482"